Jim Cramer Says “CRISPR (CRSP) Keeps Losing Money Like Moderna” – Here’s Why
We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...
health.economictimes.indiatimes2h
UK health system to offer cutting-edge gene therapy for sickle cell disease
The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...
NHS Rolls Out £1.7 Million Gene Therapy for Sickle Cell Disease
One of the world’s most expensive medicines will be used to treat some patients with sickle cell disease in England using the state-funded National Health Service.Most Read from BloombergManhattan’s M ...
Design Therapeutics: Not A Complete Washout Despite Setback
Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...
Le Lézard5h
Genomics Market to Grow by USD 5.21 Billion (2024-2028), Boosted by Rising Investments in R&D, with AI Driving Market Transformation - Technavio
Report with the AI impact on market trends - The global genomics market size is estimated to grow by USD 5.21 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR ...
Vertex downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...
Wells downgrades Vertex to Equal Weight on lack of catalysts
Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...
precisionmedicineonline45m
NICE Recommends Vertex, CRISPR Therapeutics' Casgevy for Sickle Cell Under Managed Access Deal
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.